Letrozole and norethisterone acetate in rectovaginal endometriosis.
This open-label prospective study evaluated the efficacy of letrozole (2.5 mg/day) combined with norethisterone acetate (2.5 mg/day) in the treatment of pain symptoms related to the presence of rectovaginal endometriosis. The treatment significantly and quickly decreased the intensity of symptoms, but pain recurred at 3-month follow-up; five women underwent surgery during the follow-up, and histologic examination of rectovaginal nodules revealed the presence of active endometriotic lesions.
Remorgida
Valentino
V
Department of Obstetrics and Gynecology, San Martino Hospital and University of Genoa, Genoa, Italy.
Abbamonte
Helena Luiza
HL
Ragni
Nicola
N
Fulcheri
Ezio
E
Ferrero
Simone
S
D000284:Administration, Oral; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use*; D009640:Norethindrone / Q000031:analogs & derivatives; D000077563:Norethindrone Acetate; D011446:Prospective Studies; D012002:Rectal Diseases / Q000188:drug therapy*; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D014623:Vaginal Diseases / Q000188:drug therapy*
D047072:Aromatase Inhibitors; D003280:Contraceptives, Oral, Synthetic; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole; D000077563:Norethindrone Acetate; D009640:Norethindrone